A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin

Shanghai Jiao Tong University

Status: Unknown

Conditions: Lymphoma

Treatments: Drug: liposomal doxorubicin

Study type: Observational

Funder types: Other

Identifiers

NCT04069845

Realipo-01

Details and patient eligibility

About

This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed lymphoma
• 18-80 years
• ECOG<= 2
• newly diagnosed lymphoma
• liposomal doxorubicin is planned in the treatment
• normal lung function
• no history or malignancy
• informed consented

Exclusion criteria

• history of malignancy, now in the treatment
• pregnant
• serious infection
• other uncontrollable conditions judged by the investigator

Trial design

2,000 participants in 1 patient group

liposomal doxorubicin treatment

Description:

intravenous liposomal doxorubicin

Treatment:

Drug: liposomal doxorubicin